Rare Disease Drug Development : Clinical, Scientific, Patient, and Caregiver Perspectives (2021. xxiv, 409 S. XXIV, 409 p. 36 illus., 8 illus. in color. 235 mm)

個数:

Rare Disease Drug Development : Clinical, Scientific, Patient, and Caregiver Perspectives (2021. xxiv, 409 S. XXIV, 409 p. 36 illus., 8 illus. in color. 235 mm)

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6~9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版
  • 商品コード 9783030786045

Full Description

This book provides a broad overview of rare disease drug development. It offers unique insights from various perspectives, including third-party capital providers, caregivers, patient advocacy groups, drug development professionals, marketing and commercial experts, and patients. 

A unique reference, the book begins with narratives on the many challenges faced by rare disease patient and their caregivers. Subsequent chapters underscore the critical, multidimensional role of patient advocacy groups and the novel approaches to related clinical trials, investment decisions, and the optimization of rare disease registries. The book addresses various rare disease drug development processes by disciplines such as oncology, hematology, pediatrics, and gene therapy. Chapters then address the operational aspects of drug development, including approval processes, development accelerations, and market access strategies. The book concludes with reflections on the authors' case forreal-world data and evidence generation in orphan medicinal drug development. 

Rare Disease Drug Development is an expertly written text optimized for biopharmaceutical R&D experts, commercial experts, third-party capital providers, patient advocacy groups, patients, and caregivers.

Contents

Introduction to Rare Diseases and Market Overview.- The Patient Perspective.- Select Patient Narratives.- The Caregiver Perspective.- The Critical, Multidimensional Role of Patient Advocacy Groups in Rare Disease.- A Mental Health Perspective.- Investment Decisions Related to Rare Disease Drug Development.- Optimizing Rare Disease Registries and Natural History Studies.- Novel Approaches to Clinical Trials in Rare Diseases.- Patient Benefits from Innovative Designs in Rare Diseases.- Central Nervous System Rare Disease Drug Development.- Oncologic Rare Disease Drug Development .- Hematologic Rare Disease Drug Development.- Lessons From Rare Disease and Gene Therapy Clinical Studies in Ophthalmology.- Rare Diseases in the Pediatric Population.- Cell and Gene Therapy in Rare Diseases.- The Feasibility Assessment.- The Evolving Regulatory Space and the Advent of Patient-Focused Drug Development.- Operational Aspects of Rare Disease Drug Development.- Accelerating Rare Disease Drug Development.- Select Rare Disease Drug Approvals: Lessons Learned.- A Rapid Market Access Strategy for Orphan Medicinal Products (OMPs) with Highlights Regarding the Pricing and Reimbursement Process and Barriers to Patient Use.- Integrated Life Cycle Management for Rare and Orphan Products.- The Case for Real-World Data and Real-World Evidence Generation in Rare and Orphan Medicinal Drug Development.- Closing Remarks.- 

最近チェックした商品